阿昔替尼联合特瑞普利单抗治疗转移性黏膜黑色素瘤的IB期试验
该单中心IB期试验评估了特瑞普利单抗联合阿昔替尼在晚期黑色素瘤(含初治黏膜黑色素瘤)中的安全性和初步疗效。29例初治黏膜黑色素瘤中客观缓解率48.3%(95%CI 29.4%–67.5%),中位无进展生存期7.5个月(95%CI 3.7个月–未达到)。
要点
- 联合方案耐受性可,未观察到剂量限制性毒性。
- 初治黏膜黑色素瘤客观缓解率达48.3%,中位PFS 7.5个月。
- 结论需随机III期试验(含非亚洲人群)验证。
核心结论
- 特瑞普利单抗联合阿昔替尼耐受性良好,在初治转移性黏膜黑色素瘤中显示出有前景的抗肿瘤活性。
- 该联合方案需在包含非亚洲人群的随机III期试验中验证后方可成为标准治疗。
研究设计与样本
- 单中心、开放标签、IB期试验,采用剂量递增和队列扩展设计。
- 特瑞普利单抗1或3 mg/kg每2周静脉输注,联合阿昔替尼5 mg口服每日两次,直至确认疾病进展、不可接受毒性或自愿退出。
- 主要目标为安全性,次要目标包括疗效、药代动力学、药效动力学、免疫原性和肿瘤组织生物标志物。
主要发现
- 未观察到剂量限制性毒性。
- 3级及以上TRAEs发生于39.4%的患者。
- 29例化疗初治黏膜黑色素瘤中,14例(48.3%;95% CI,29.4%至67.5%)达到客观缓解。
- 按RECIST 1.1标准,中位无进展生存期为7.5个月(95% CI,3.7个月至未达到)。
关键数值与推荐
- 初治黏膜黑色素瘤客观缓解率48.3%(95% CI,29.4%至67.5%)。
- 中位无进展生存期7.5个月(95% CI,3.7个月至未达到)。
- 3级及以上治疗相关不良事件发生率39.4%。
临床怎么用
- 对于初治转移性黏膜黑色素瘤,特瑞普利单抗联合阿昔替尼可作为潜在治疗选择,但需在随机III期试验验证前谨慎使用。
- 治疗期间需监测常见不良事件,包括腹泻、蛋白尿、手足综合征、乏力、肝酶升高、高血压、甲状腺功能异常及皮疹。
局限性
- 单中心、IB期、开放标签、非随机设计,样本量小。
- 入组患者均为亚洲人群,结果需在包含非亚洲人群的随机III期试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory to either therapy alone. PATIENTS AND METHODS: We conducted a single-center, phase IB trial evaluating the safety and preliminary efficacy of toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1 in combination with the VEGF receptor inhibitor axitinib in patients with advanced melanoma, including patients with chemotherapy-naïve mucosal melanomas (88%). Patients received toripalimab at 1 or 3 mg/kg via intravenous infusion every 2 weeks, in combination with axitinib 5 mg orally twice a day, in a dose-escalation and cohort-expansion study until confirmed disease progression, unacceptable toxicity, or voluntary withdrawal. The primary objective was safety. Secondary objectives included efficacy, pharmacokinetics, pharmacodynamics, immunogenicity, and tumor tissue biomarkers. RESULTS: Thirty-three patients were enrolled. No dose-limiting toxicities were observed. Ninety-seven percent of patients experienced treatment-related adverse events (TRAEs). The most common TRAEs were mild (grade 1 or 2) and included diarrhea, proteinuria, hand and foot syndrome, fatigue, AST or ALT elevation, hypertension, hypo- or hyperthyroidism, and rash. Grade 3 or greater TRAEs occurred in 39.4% of patients. By the cutoff date, among 29 patients with chemotherapy-naïve mucosal melanoma, 14 patients (48.3%; 95% CI, 29.4% to 67.5%) achieved objective response, and the median progression-free survival time was 7.5 months (95% CI, 3.7 months to not reached) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CONCLUSION: The combination of toripalimab plus axitinib was tolerable and showed promising antitumor activity in patients with treatment-naïve metastatic mucosal melanoma. Patients enrolled in this study were all Asian, and this combination therapy must be validated in a randomized phase III trial that includes a non-Asian population before it can become a standard of care.
引用
- Sheng X, Yan X, Chi Z, et al. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. J Clin Oncol. 2019. PMID: 31403867. doi:10.1200/JCO.19.00210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。